WO1995027063A2 - Rfb-retrovirusgenom - Google Patents

Rfb-retrovirusgenom Download PDF

Info

Publication number
WO1995027063A2
WO1995027063A2 PCT/EP1995/001234 EP9501234W WO9527063A2 WO 1995027063 A2 WO1995027063 A2 WO 1995027063A2 EP 9501234 W EP9501234 W EP 9501234W WO 9527063 A2 WO9527063 A2 WO 9527063A2
Authority
WO
WIPO (PCT)
Prior art keywords
rfb
retrovirus
genome
retrovirus genome
bone regeneration
Prior art date
Application number
PCT/EP1995/001234
Other languages
English (en)
French (fr)
Other versions
WO1995027063A3 (de
Inventor
Joerg Schmidt
Wolfgang Gimbel
Paul-Guenter Strauss
Volker Erfle
Finn Skou Pedersen
Lene Pedersen
Mette Oestergaard
Original Assignee
Gsf Forschungszentrum Umwelt
Joerg Schmidt
Wolfgang Gimbel
Strauss Paul Guenter
Volker Erfle
Finn Skou Pedersen
Lene Pedersen
Mette Oestergaard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gsf Forschungszentrum Umwelt, Joerg Schmidt, Wolfgang Gimbel, Strauss Paul Guenter, Volker Erfle, Finn Skou Pedersen, Lene Pedersen, Mette Oestergaard filed Critical Gsf Forschungszentrum Umwelt
Priority to EP95916604A priority Critical patent/EP0755448A1/de
Priority to AU23050/95A priority patent/AU2305095A/en
Publication of WO1995027063A2 publication Critical patent/WO1995027063A2/de
Publication of WO1995027063A3 publication Critical patent/WO1995027063A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Erfindungsgemäß wird die vollständige Gensequenz des RFB-Provirusgenoms angegeben. Es wird vorgeschlagen, daß RFB-Retrovirus und andere, damit verwandte osteoinduktive Retroviren zur Entwicklung eines Therapeutikums zur Behandlung von Knochenerkrankungen, insbesondere zur Induktion von Knochenneubildung, einzusetzen. Erfindungsgemäß wurden die codierenden Bereiche des RFB-Retrovirus als die für die Knochenneubildung verantwortlichen Genomabschnitte identifiziert.
PCT/EP1995/001234 1994-04-05 1995-04-05 Rfb-retrovirusgenom WO1995027063A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95916604A EP0755448A1 (de) 1994-04-05 1995-04-05 Rfb-retrovirusgenom
AU23050/95A AU2305095A (en) 1994-04-05 1995-04-05 Rfb retrovirus genome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4411718.3 1994-04-05
DE4411718A DE4411718A1 (de) 1994-04-05 1994-04-05 RFB-Retrovirusgenom

Publications (2)

Publication Number Publication Date
WO1995027063A2 true WO1995027063A2 (de) 1995-10-12
WO1995027063A3 WO1995027063A3 (de) 1995-12-14

Family

ID=6514671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/001234 WO1995027063A2 (de) 1994-04-05 1995-04-05 Rfb-retrovirusgenom

Country Status (4)

Country Link
EP (1) EP0755448A1 (de)
AU (1) AU2305095A (de)
DE (1) DE4411718A1 (de)
WO (1) WO1995027063A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004375A1 (de) * 1994-08-01 1996-02-15 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Retrovirus-induzierte osteoklasten-modulation für die osteoporose-therapie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572737A2 (de) * 1992-06-04 1993-12-08 The Research Foundation For Microbial Diseases Of Osaka University Gag-Env Fusion-Antigen aus HIV
WO1994005780A1 (en) * 1992-08-28 1994-03-17 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572737A2 (de) * 1992-06-04 1993-12-08 The Research Foundation For Microbial Diseases Of Osaka University Gag-Env Fusion-Antigen aus HIV
WO1994005780A1 (en) * 1992-08-28 1994-03-17 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF VIROLOGY, Bd.55, Nr.3, Seiten 521 - 526 A. DUSTY MILLER ET AL. 'Deletion of the gag region from FBR murine osteosarcoma virus does not affect its enhanced transforming activity' *
JOURNAL OF VIROLOGY, Bd.66, Nr.10, Seiten 6186 - 6190 L. PEDERSEN ET AL. 'Molecular Cloning of Osteoma-Inducing replication Competent Murine Leukemia Viruses from the RFB Osteoma Virus Stock' *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004375A1 (de) * 1994-08-01 1996-02-15 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Retrovirus-induzierte osteoklasten-modulation für die osteoporose-therapie

Also Published As

Publication number Publication date
EP0755448A1 (de) 1997-01-29
DE4411718A1 (de) 1995-10-12
WO1995027063A3 (de) 1995-12-14
AU2305095A (en) 1995-10-23

Similar Documents

Publication Publication Date Title
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
TR199802421T2 (xx) Doku yenilenmesini d�zenleyen maddeler.
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
EP1147776A3 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
MX9700237A (es) Combinaciones inhibidoras de proteasa retroviral.
ID26956A (id) Pencegahan raf kinase menggunakan simetris dan nonsimetris yang digantikan diphenil urea
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
GR3036254T3 (en) Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
WO1994005791A3 (en) Dorsal tissue affecting factor and compositions
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
BR9711647A (pt) Novos derivados de ácido dicafeoilquìmico, seu uso, composições com os mesmos e métodos de tratamento usando-os.
BR9814945A (pt) Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
WO1995027063A3 (de) Rfb-retrovirusgenom
EP0373771A3 (de) Neue pharmazeutische Anwendungen von Cystatinen
NO965556L (no) Trippelkombinasjon mot HIV
IT8919735A0 (it) Procedimento per la riduzione del cod da reflui industriali o urbani.
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
AU698242B2 (en) Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
DE69531678D1 (de) Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie
WO1998024421A3 (en) Use of dextrin sulphate for the treatment of highly vascular tumours
EP0624372A3 (de) Arzneimittel zur Behandlung von HIV-Infektionen.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TT UA KE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1995916604

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995916604

Country of ref document: EP

ENP Entry into the national phase in:

Ref country code: US

Ref document number: 1997 718393

Date of ref document: 19970311

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase in:

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995916604

Country of ref document: EP